Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Active Not Recruiting2
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT03866382Phase 2Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

NCT02721732Phase 2Active Not Recruiting

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

NCT03587662Phase 2Active Not RecruitingPrimary

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Showing all 3 trials

Research Network

Activity Timeline